Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07407907
Active, not recruiting Not applicable

Effect of IMB Model-Based Education for Women With Menopausal Hot Flashes

NCT07407907 · tracked via the Priya Life Science Turkey tracker
Sponsor
Marmara University
Phase
Not applicable
Started
2024-02-07
Last updated
2026-02-12

Condition(s) studied

Menopausal Hot Flashes

Investigational drug(s) / intervention(s)

IMB Model-Based Education Program

IMB Model-Based Education Program: A structured education program based on the Information-Motivation-Behavioral Skills (IMB) model was delivered to women experiencing hot flashes during menopause. The intervention aimed to enhance participants' knowledge, motivation, and behavioral skills related to the management of menopausal hot flashes. The educational content included information on the physiology of hot flashes, lifestyle modifications, symptom management strategies, coping techniques, and skills to support healthy behaviors. The program was delivered through planned educational sessions.

Study summary

This study was conducted to examine the effect of an education program based on the Information-Motivation-Behavioral Skills (IMB) Model on the level of hot flashes, overall menopausal symptoms, and quality of life in women experiencing hot flashes during the menopausal period.

The study consisted of an intervention group and a control group. The intervention group received a structured education program based on the IMB Model, while no education, counseling, or care intervention was provided to the control group. Both groups were assessed at baseline, and at the 1st and 3rd months following the intervention.

It is expected that the findings obtained from this study will demonstrate the effectiveness of IMB Model-based education in the management of menopausal vasomotor symptoms and contribute to the development of evidence-based nursing practices for women during the menopausal period.

Eligibility

Sex
FEMALE
Min age
44 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria:Women aged between 44 and 60 years. Women in the perimenopausal or postmenopausal period. A score of ≥ 10 on the Menopause-Specific Hot Flash Scale. No diagnosis of severe chronic disease and no regular medication use related to such conditions. Not receiving Hormone Replacement Therapy (HRT). No diagnosed mental disorder requiring medical treatment. Able to read, write, speak, and understand Turkish, with no language barriers. Willingness to participate in the study and provision of voluntary informed consent. \- Exclusion Criteria:Not meeting the inclusion criteria. Initiation of Hormone Replacement Therapy during the study period. Refusal to participate in the study. Occurrence of an unexpected acute illness during the study period. Withdrawal from the study at any stage by personal choice. Incomplete completion of study questionnaires or forms after enrollment. \-

Primary outcome measure(s)

  • Hot Flash-Related Daily Interference — Baseline (pre-intervention), 1 month, and 3 months
    Hot flash-related daily interference was assessed using the Hot Flash Related Daily Interference Scale, which evaluates the extent to which hot flashes interfere with daily activities and quality of life.

Trial sites (1)

FacilityCityRegionStatus
Cumhuriyet University Health Services Application and Research Hospital, Obstetrics and Gynecology Outpatient Clinic Sivas Sivas

More Marmara University trials in Turkey

Investigation of Medial Longitudinal Arch and Foot Function in Patients With Lipedema Recruiting
AI-Based Prediction of Root Coverage Outcome From Intraoral Photographs Recruiting
Comparison of Intrathecal Morphine and Rectus Sheath Block for Postoperative Pain Management After Lower Abdominal Surgery With Midline Incision Active, not recruiting
The Effect of Inspiratory Exercises on Diaphragm and Intercostal Muscle Thickness in Stroke Patients Starting soon
Physicians' Perception About Patient Pain in Flexible Cystoscopy With Local Anesthesia Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07407907 on ClinicalTrials.gov ↗ ← All trials in Turkey